'Sick Men Are': Some Stories From The UK Crisis | Pharmaceutical companies

'We You want to see more of Britain,” Opportunity, Rachel Reeves, He promoted the big trading companies This month, when he showed that the government was willing to increase the cost it pays for the toys of the NHS. Ministers must announce a Change over prices Soon, which will end this weekend.

But the magnitude of the increase was not confirmed. The big question is whether it will be generous enough to guarantee companies close to the UK economy.

Caught in the middle is 163,600 people Attempts to drive activity in Biopharmaceuticals, which generated annual sales of $98.4bn in 2023-24.

The problems began in September, and were chosen by the US drug group, known as Msd in Europe, to arrangements for £1bn researchers in London.

The move seemed to set off a domino effect. About £2bn of the pharma project has been copied or stopped So far this year, threatening more than 1,000 jobs.

graph

This picture is complicated by geopolitics. Donald Trump has been pressuring Merck and its competitors to reduce their US prices, which can be three times higher than those in the UK and other countries, where the health sector often has the upper hand in negotiations.

Courage patrickscience, has tried to destroy line. Ministers I think they have Drag the Targets Raising these funds will pay for pharmaceutical films by 25%. This would require additional funding, adding to Reeves' low budget ahead of the November 26 budget.

Meanwhile, a shadow hangs over the UK, whose leaders say the line could cause long-term damage to manufacturers – and ultimately to patients.

Loving boss

“As a sustainable organization, we are concerned,” says Giless Lomax, Executive Director of Kalanger Sporophy (SMA). He is the father of twins with SMA type 2, a neurological condition that causes muscle wasting and weakness.

Lomax says “Patients will suffer” if the suspension continues, adding: “The geopolitical situation, it's very difficult and we have to keep the patient in the middle of this. But we have to keep the patient in the middle of this.

“It is very important that the magazine be disposed of quickly,” he adds. “For people with sma, every minute they start to build muscle, it starts to deteriorate, and the failure to find treatment options can be very difficult.”

Drugs don't just cost money, they can save money, they argue.

Zolgeensma, an injection made by the Swiss manufacturer Novaritis, is one of three gene therapies on the market that treat sma. It has an eye-watering cost to the NHS of £1.8m. But if given early, before symptoms develop, it can help children live a normal life.

Lomax said: “The drugs are expensive, but it's a very good life. “The childcare program costs £300,000 a year. So in six years, you've paid your dues.”

Graduate of Science

David Poolman, 22, graduated from the University of Bath with a Biomedical Science degree in July and wants to work in Farma when he gets his chance.

Poolman says: “It's not going to be encouraging if companies are pulling out of the UK,” says Poloman. In Tough Job Completion MarketHe says there is a lot of competition for PhD afs, even though he has experience from New York University.

It is difficult to find a research assistant, who has only one part of the applicant who has written a reason. The graduates are suffering a lot, and 35% will throw a job in the employer last year.

“In the industry, there are few jobs available because the industry knows the money and the flow,” Pontho said. “Whereas in the universities, there are many positions that are advertised, but the competition is very high for them.”

Poolman's goal is to be able to complete a PHD before applying for a company audit, or starting a new company.

“I wouldn't say I'm very positive about science in the UK. However, there was Extreme Heat At University College London one day in the treatment of Huntington's disease, and neurodegenerative is the area I want to go into. This gives me hope. “

The ancient science

Janethan Innovating Clocks Invention (IICON)which brings in sales, for Schools and Hospitals.

He says his clinical trials remain strong but he is worried. Infectious diseases are “a broken market because the crisis has forced the price of antibiotics to a low level”.

Although the lower prices are good for patients and the NHS budget, it also means that the companies are not planning to spend more, he says, and some organizations, such as Bill Foumught, to develop new drugs.

But medical experts argue that it is not enough, and hospitals have registered Rising in diseases from Superbugs This is related to antibiotics, which cause high mortality.

Ngomingay warns that if the same thing happens with other drugs, cure cancer later, stop in the UK. “

Companies need the right number, he says. The question is, How many limits?

Lab designer

Overlooked by the entrance to the King's Cross in London to stand half research center, the glass that was installed to establish the Hub Canity Hub. The 10-story building would have 800 staff, with laboratories on the lower levels and offices above.

Michaelman, the head of British schools, a place with several houses close together in the area, known as the quarter, remembers that Msd announced its earnings In London in 2017 it was a big moment.

“The decision was made a few years after the (nearby) Francis Crick Crick Crick Crick Crick Institute established a scientific concept in London. And so there were some, they thought he was the first.”

But the speed of money is slow. Around 10% of UK properties are in default, with a problem in June, according to data from the finance ministry. After the record in 2024, it has risen to its lowest level in 12 years, and no new lab construction has started across the UK since last summer.

The genius is assured that the number of views and people who can do it has not decreased, and now he is counting small files to meet the combined space and large groups.

His prediction calls for deep optimism: “Maybe we're missing some of the demand for pharma for a long time. But with what's being built, the end of the market should be enough to carry that space.”